SPAC — NASDAQ: ACAAU

Averin Capital Acquisition Corp.

Cayman Islands blank check company formed to pursue a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The Company is conducting a $250,000,000 IPO of 25,000,000 units at $10.00 per unit and intends to complete an initial business combination within 24 months (or 27 months if a definitive agreement is executed within 24 months) from the closing of the offering.

Live Quote NASDAQ

Loading stock data…

Last updated: —

About the Company

Company Overview

Averin Capital Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

The Company has not selected any business combination target and has not initiated any substantive discussions with any target. While it may pursue an initial business combination in any business or industry, it intends to focus on opportunities at the intersection of technology and health that can benefit from its management team’s operational expertise.

IPO Size

$250M

Focus Sectors

Health · Technology

Exchange

Nasdaq: ACAAU

Disclosures

News & SEC Filings

Latest News

  • Loading press releases…
View All News

SEC Filings

  • Loading SEC filings…
View All Filings

Our Team

Leadership

Officers

DB

Dr. David A. Berry

Chairman & Chief Executive Officer

Dr. Berry has served as Chairman and Chief Executive Officer since October 21, 2025. He is the Co-Founder and Managing Partner of Averin Capital LLC, an investment firm focused on transforming health through technology. He currently serves on the boards of Oaktree Acquisition Corp. III Life Sciences, Hologen Inc., Biolinq Incorporated, Osler Diagnostics Limited (Chairman), and Salma Health, Inc. (Board Observer), and previously served as a director of Omega Therapeutics, Inc. (NASDAQ: OMGA) and Valo Health, Inc. Dr. Berry brings nearly two decades of experience in investing, entrepreneurship and company building across biotechnology, health-technology and deep-tech. Prior to Averin, he was a General Partner at Flagship Pioneering Inc., where he co-founded and helped build over 30 companies, including Moderna, Seres Therapeutics, Indigo Agriculture and Inari Agriculture. In 2019, he founded Valo Health, Inc. and served as CEO through 2023, guiding the company from inception to unicorn status and leading the raise of over $500 million and a $5.1 billion strategic transaction with Novo Nordisk A/S. He previously served as CEO and a director of Axcella Health, Inc. (Nasdaq: AXLA) (2009–2020) and as CEO and a director of Evelo Biosciences (Nasdaq: EVLO) (2014–2018). Dr. Berry earned his M.D. from Harvard Medical School and his Ph.D. in Biological Engineering from MIT, and holds a B.S. in Brain and Cognitive Sciences from MIT.

AL

Alex Lau

Chief Financial Officer & Secretary

Mr. Lau has served as Chief Financial Officer and Secretary since October 21, 2025. He has served as Partner and Head of Operations at Averin Capital since February 2025, leading finance, investor relations, compliance, and firm operations. From October 2014 to January 2025, he held operations and finance leadership roles at OpenView Venture Partners, most recently as Partner, Operations. Mr. Lau holds a B.S. in Finance from Bentley University and an M.B.A. from Boston College.

Director Nominees

US

Ulrik Schulze

Director Nominee

Mr. Schulze is the Managing Director and Chairman of Sanrigen GmbH, a Swiss advisory firm specializing in strategic and operational consulting for life-science companies. He also serves as a Senior Advisor to The Boston Consulting Group (Switzerland) and as a Non-Executive Director and Audit Committee member of BioVersys AG (SIX: BIOV), as well as a Non-Executive Director of Biograil Aps and Indivi AG. Mr. Schulze is an Advisor to Averin Capital and a limited partner in Averin Health Opportunities Fund I. He previously served as Chairman of ReproNovo SA (2021–2023) and was formerly a Managing Director and Senior Partner at BCG, where he led BCG’s global Biopharma Sector. He holds an M.Sc. in Chemical Engineering and a Ph.D. in Biotechnology from the Technical University of Denmark.

GB

Graeme Bell

Director Nominee

Mr. Bell has served as Group Chief Financial Officer of Owkin, Inc. since May 2025, an AI and computational biology company with offices in London, Paris, New York and Boston. He also serves on the board of Mindstate Design Labs Inc. (since December 2025), is a Board Advisor to Symbiotix Health Ltd. (since March 2025), and is a University-Appointed Mentor at Loughborough University Science and Enterprise Park (since September 2024). He is the Founder and Principal of ValueCycle LLC. From 2020 to 2024, he held senior executive roles at Valo Health Inc., including Interim President and CEO (2024) and EVP roles spanning COO, CFO, CHRO and broader corporate functions. He previously served as EVP and CFO of Tmunity Therapeutics Inc., Intellia Therapeutics Inc., and Anacor Pharmaceuticals Inc., and spent over 20 years at Merck & Co., Inc. in finance and investor relations leadership roles. Mr. Bell received an M.B.A. in Finance and Marketing from Durham University Business School and is a Fellow of the Chartered Institute of Management Accountants (FCMA).

MS

Mary T. Szela

Director Nominee

Ms. Szela has served as Chief Executive Officer of TriSalus Life Sciences, Inc. since January 2018 and serves on its board of directors. She also currently serves on the boards of Absci Corporation and Kura Oncology Inc. From 2016 to 2017, she served as CEO of Novelion Therapeutics Inc., and from 2013 to 2015, as CEO of Melinta Therapeutics, Inc., leading executive management, commercial and clinical operations, and corporate strategy. Earlier in her career, she spent more than 25 years at Abbott Laboratories in senior leadership roles, including SVP, Global Strategic Marketing and Services, President, U.S. Pharmaceuticals, and VP, U.S. Commercial Operations. Ms. Szela has previously served on numerous public company boards, including Novo Nordisk A/S and other biotechnology companies. She received an M.B.A. from the University of Illinois at Chicago and a B.S. from the University of Illinois at Chicago College of Nursing.

Governance

Corporate Governance

Committee Composition Matrix

Director Independent Audit Committee Compensation Committee
Graeme Bell ✓ Chair · FE Member
Mary T. Szela ✓ Member Chair
Ulrik Schulze ✓ Member Member
Chair Member FE = Audit Committee Financial Expert ✓ Independent

Charter Documents

Code of Business Conduct and Ethics

View on SEC.gov →

Audit Committee Charter

View on SEC.gov →

Compensation Committee Charter

View on SEC.gov →

Stay Informed

Subscribe to receive news and SEC filings directly in your inbox.

We respect your privacy. Unsubscribe at any time.